89796-22-5

Usage

Uses

Used in Organic Synthesis:
1-(2-BROMO-ETHYL)-PIPERIDINE HYDROBROMIDE is used as a building block in organic synthesis for the production of various pharmaceuticals and other biologically active compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(2-BROMO-ETHYL)-PIPERIDINE HYDROBROMIDE is used as an intermediate in the synthesis of various drugs, contributing to the development of new therapeutic agents.

InChI:InChI=1/C7H14BrN/c8-4-7-9-5-2-1-3-6-9/h1-7H2

Upstream product

• 110-89-4 piperidine 
• 3040-44-6 1-piperidinoethanol 

Downstream Products

• 1101118-83-5 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-methyl-5-nitro-N-(2-(piperidin-1-yl)ethyl)benzenesulfonohydrazide 

Relevant academic research and scientific papers

Self-assembly of pseudo-rotaxane and rotaxane complexes using an electrostatic slippage approach

The protonation of a cyclic tertiary amine, integrated into the structure of a dumbbell-shaped guest molecule, accelerates the sliding of the guest through the cavity of a crown ether macrocycle to yield a stable pseudo-rotaxane complex. The use of an amine with the appropriate ring size followed by a proton transfer reaction leads to the formation of an interlocked rotaxane species.

Electrooxidative cyclization of hydroquinolyl alcohols, hydroquinolylamines, and dimethyl aminomalonates

Several hydroquinolyl alcohols and amines were electrochemically oxidized in methanol in the presence of sodium methoxide and potassium iodide to afford the corresponding intramolecular cyclization products. Furthermore, several amino malonates were electrochemically oxidized to yield the corresponding heterocyclic compounds through an intramolecular carbon-carbon bond formation in the presence of sodium cyanide in methanol. CSIRO 2007.

Aminoindazole derivatives

A compound of the formula (I): STR1 wherein W1 and W2 each independently is a hydrogen atom or a STR2 group wherein Y is a n-C1-6 alkylene group or a n-C1-6 alkylene group having a C1-6 alkyl group substituent; and R1 and R2 each independently is a hydrogen atom or a C1-6 alkyl group, and STR3 group in STR4 group may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C1-3 alkyl group or a methoxy group; Z2 is a hydrogen atom or an amino group; when W1 and W2 are both hydrogen atoms, Z1 is a hydroxyl group or an iodine atom and Z2 is hydrogen atom, or Z1 and Z2 are both amino groups; when Z1 and Z2 are both hydrogen atoms, the STR5 group in either W1 or W2 is a morpholino group; when Z1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z2 is a hydrogen atom; when Z1 is an amino group, Z2 is a hydrogen atom or an amino group; when Z1 is a methyl group, a methoxy group or an amino group, Z1 is in the 5-position; when Z1 is an iodine atom, Z1 is in the 5- or 7-position; and when Z1 and Z2 are both amino groups, Z1 and Z2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof which compounds have pharmaceutical utility, e.g.: treating inflammation.

3-Aminoindazole derivatives

A compound of the formula (I): STR1 wherein W1 is a hydrogen atom or a STR2 group wherein Y is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R1 and R2 each independently is a hydrogen atom or a C1-6 alkyl group and R1 and R2 may form a C4-6 heterocyclic ring or a nitrogen-containing C4-6 heterocyclic ring together with the adjacent nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; W2 is a hydrogen atom or a STR3 group wherein Z is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R3 and R4 each independently is a hydrogen atom or a C1-6 alkyl group and R3 and R4 may form a C4-6 heterocyclic ring or a nitrogen-containing C4-6 heterocyclic ring together with the adjacent nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; when W1 is a hydrogen atom, W2 is the STR4 group; and when W2 is a hydrogen atom, W1 is the STR5 group; and the pharmaceutically acceptable acid addition salt thereof having antiinflammatory, analgesic and digestive tract ulcer suppressing activity.